12 hrs ago
AstraZeneca PLC Fights With Pediatrician Group Over Preemie Drug Guidelines
Once again, there is controversy over an expensive drug for premature babies. At issue are new American Academy of Pediatrics guidelines that recommend scaling back usage of a drug called Synagis, which costs several thousand dollars and is sold by AstraZeneca 'sAZN.LN -0.23% MedImmune unit, because evidence shows the medicine benefits few children ... (more)
16 hrs ago
Merck 2Q profit more than doubles
A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts' expectations.
Mon Jul 28, 2014
Investor's Business Daily
Pfizer, Merck, Amgen Near Q2 Earnings Reports
In his downgrade note Monday, BMO Capital Markets analyst Alex Arfaei noted that patent expirations are going to continue through next year.
AstraZeneca and QIAGEN enter collaboration to develop diagnostic test ...
IRESSA is an epidermal growth factor receptor tyrosine kinase inhibitor that blocks the signals from the EGFR, which leads to tumour growth.
AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291
The companion diagnostic test is designed to identify epidermal growth factor receptor mutations in both tumour tissue and plasma derived from patients with NSCLC, and to optimise the clinical development of AZD9291 for patients who are resistant to first -generation EGFR tyrosine kinase inhibitors .
Tue Jul 22, 2014
Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial
The Phase I/II immunotherapy study will evaluate the safety and efficacy of lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus -associated cervical cancer and HPV-associated head and neck cancer.
Fri Jul 18, 2014
AstraZeneca PLC Unveils Plans For "See-Through" Labs In Cambridge
The days of secretive drug research will soon be a distant memory for the scientists at one of Britain's biggest pharma companies.
Broker tips: GlaxoSmithKline, AstraZeneca, Housebuilders
Panmure Gordon said it is "not expecting fireworks" from GlaxoSmithKline's second-quarter results due out next Wednesday.
Thu Jul 17, 2014
Xalkori: Pfizer's Lung Cancer Drug Might Get A Future Boost In Sales
It is no secret that Pfizer has had a rocky first half this year. The difficulties around its attempt to acquire AstraZeneca were compounded by Q1 sales that missed market expectations by 9 percent.
Wed Jul 16, 2014
AstraZeneca plc Receives "Buy" Rating from Citigroup Inc.
's stock had its "buy" rating reiterated by equities research analysts at Citigroup Inc. in a research note issued to investors on Wednesday.
I Believe AstraZeneca Is Fairly Valued
AstraZeneca PLC , a $94.71 billion market cap company is a giant in the drug industry and has a trailing P/E ratio that indicates that the stock is relatively undervalued .
Customer Interaction Solutions
Alexion Announces the Appointments of David R. Brennan, M. Michele...
Alexion Pharmaceuticals, Inc. today announced the appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to the Company's Board of Directors, effective immediately.
Walgreen Tax Inversion: Masking A Weak Business?
Walgreen shares are trading near an all-time high and at a fancy multiple for a drug store chain - a forward PE ratio of more than 20 - as investors focus on whether the company will engage in a tax inversion as part of its expected acquisition of the 55% of Alliance Boots, the European drug store chain, not already owned by Walgreen.
Tue Jul 15, 2014
U.S. 'inversion' takeovers strike fear in Europe
Bankers in Europe say their clients are concerned about being taken over by U.S. companies as the trend of so-called inversion deals continues.
AstraZeneca plc Given Average Recommendation of "Hold" by Analysts
AstraZeneca plc has earned a consensus rating of "Hold" from the twenty-two analysts that are currently covering the stock, AnalystRatings.NET reports .
AstraZeneca plc PT Lowered to GBX 4,790
The firm currently has a "hold" rating on the stock. Jefferies Group's target price would suggest a potential upside of 9.62% from the stock's previous close.
Mon Jul 14, 2014
Medtronic Not Sticking Around To Rearrange Chairs On The Titanic
We also think such moves implicitly reveal their company's views on the direction of future fiscal deficits in the US, and by extension, the belief that the financial burden will only increase on future generations.
Wed Jul 09, 2014
Salix Pharmaceuticals: - Better Deal Than It Is Being Viewed'
On July 1, Salix Pharmaceuticals jumped 14% after announcing positive results from a drug trial .
Here's Why Pfizer Inc. Should Buy GlaxoSmithKline
In the aftermath of pharmaceutical giant Pfizer failing in its repeated attempts to acquire European drug maker AstraZeneca , investors may be wondering what's next.
Tue Jul 08, 2014
Fund Manager Dumps Biggest Investment Into AstraZeneca PLC
Veteran life sciences investor Neil Woodford has put his money where his mouth is by choosing AstraZeneca as the single biggest investment for his new fund.